ClinicalTrials.gg
CompletedNCT06634797Updated Feb 4, 2026Results posted

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

A Phase 4 interventional study of mRNA-1273.712 and Placebo in Healthy Volunteers, sponsored by ModernaTX, Inc.. Completed at 24 sites in United States. Open to participants aged 12 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
12 Years to 30 Years
Sex
All
01

Study summary

The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • mRNA-1273.712
  • Vaccine
  • Cardiac Troponin
03

In context

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Investigator's assessment that participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures.
  2. Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  3. use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  1. History of anaphylaxis or severe reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic.
  2. Has known history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 months prior to enrollment.
  3. Has a documented history of myocarditis or pericarditis.
  4. Is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) less than 72 hours prior to or at the Screening Visit or Day 1.
  5. Has known conditions that may cause elevated cTnI.

    • Cardiac disease/conditions including rhythm disorders and congenital heart disease
    • Diabetes
    • Uncontrolled hypertension (defined as systolic blood pressure >140 millimeter of mercury (mmHg) or diastolic blood pressure >90 mmHg)
    • Alcohol or substance abuse
    • Kidney disease
    • Severe obesity, defined as (BMI) ≥40 kilograms per square meter (kg/m\^2) (>20 years) or severe obesity defined as BMI for sex and age ≥120% of the 95th percentile [BMI ≥35 kg/m\^2] (for 12 to 20 years)
  6. Currently has symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization for worsening disease, at the discretion of the Investigator.
  7. Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment.
  8. Reported history of congenital or acquired immunodeficiency (eg, [HIV]), condition or immune-mediated disease, asplenia, or recurrent severe infections disease.
  9. History of Guillain-Barré syndrome.
  10. Receipt of the following:

    • Coronavirus disease 2019 (COVID-19) vaccine within 3 months prior to the first injection or if planning to receive at any time during the study (except for study intervention).
    • Any other licensed vaccine within 28 days before the study injection or planned receipt prior to end of study (EOS).
    • Systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for ≥10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
    • Systemic immunoglobulins or blood products within 3 months prior to the Screening/Baseline Visit or plans for receipt during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,000 participants (actual)

Study arms

  • Experimental
    Sequence 1: mRNA-1273.712 then Placebo

    Participants will receive mRNA-1273.712 followed by placebo 28 days later.

    Biological: mRNA-1273.712 · Biological: Placebo

  • Experimental
    Sequence 2: Placebo then mRNA-1273.712

    Participants will receive placebo followed by mRNA-1273.712 28 days later.

    Biological: mRNA-1273.712 · Biological: Placebo

Interventions

  • BiologicalmRNA-1273.712

    Intramuscular (IM) injection.

  • BiologicalPlacebo

    Sodium chloride for IM injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)

    Elevated cTnI was defined as \>53.53 picograms per milliliter (pg/mL) in males and \>38.64 pg/mL in females. One participant who was included in the analysis, had an elevation of cTnI pre-injection of study intervention on Day 1 and had a normal value of cTnI pre-injection of study intervention on Day 29. Note that other factors such as physical activity can affect cTnI.

    Time frame: Day 4 and Day 32

Secondary outcomes

  1. Number of Participants With Elevated cTnI Level at Day 1 (Baseline)

    Elevated cTnI was defined as \>53.53 pg/mL in males and \>38.64 pg/mL in females.

    Time frame: Pre-injection 1: Day 1

  2. Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)

    Elevated cTnI was defined as \>53.53 pg/mL in males and \>38.64 pg/mL in females.

    Time frame: Day 29 and Day 57

  3. Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in birth defects or was an important medical event. A MAAE was defined as an AE that led to an unscheduled visit to a healthcare practitioner. Investigators reported AEs as AESIs based on pre-defined criteria. All suspected cases of cardiomyopathy and non-infectious myocarditis, pericarditis, and myopericarditis were reported as AESIs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Adverse Events' module.

    Time frame: Day 1 up to Day 57

07

Results

Posted Feb 4, 2026

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712
Started500500
Received study vaccination500497
Completed438424
Not completed6276
Withdrew: Other than specified11
Withdrew: Withdrawal by subject1221
Withdrew: Physician decision33
Withdrew: Lost to follow-up4648
Withdrew: Adverse event01
Withdrew: Screen failure02

Outcome measures

PrimaryNumber of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)

Elevated cTnI was defined as \>53.53 picograms per milliliter (pg/mL) in males and \>38.64 pg/mL in females. One participant who was included in the analysis, had an elevation of cTnI pre-injection of study intervention on Day 1 and had a normal value of cTnI pre-injection of study intervention on Day 29. Note that other factors such as physical activity can affect cTnI.

Time frame:
Day 4 and Day 32
Reported as:
Count of participants · Participants
Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)
ParticipantsmRNA-1273.712Placebo
Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)10
SecondaryNumber of Participants With Elevated cTnI Level at Day 1 (Baseline)

Elevated cTnI was defined as \>53.53 pg/mL in males and \>38.64 pg/mL in females.

Time frame:
Pre-injection 1: Day 1
Reported as:
Count of participants · Participants
Number of Participants With Elevated cTnI Level at Day 1 (Baseline)
ParticipantsSequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712
Number of Participants With Elevated cTnI Level at Day 1 (Baseline)25
SecondaryNumber of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)

Elevated cTnI was defined as \>53.53 pg/mL in males and \>38.64 pg/mL in females.

Time frame:
Day 29 and Day 57
Reported as:
Count of participants · Participants
Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)
ParticipantsmRNA-1273.712Placebo
Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)48
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in birth defects or was an important medical event. A MAAE was defined as an AE that led to an unscheduled visit to a healthcare practitioner. Investigators reported AEs as AESIs based on pre-defined criteria. All suspected cases of cardiomyopathy and non-infectious myocarditis, pericarditis, and myopericarditis were reported as AESIs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Adverse Events' module.

Time frame:
Day 1 up to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs), Medically-attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Adverse Events Leading to Withdrawal
ParticipantsSequence 1 (mRNA-1273.712 - Placebo): mRNA-1273.712Sequence 1 (mRNA-1273.712 - Placebo): PlaceboSequence 2 (Placebo - mRNA-1273.712): PlaceboSequence 2 (Placebo - mRNA-1273.712): mRNA-1273.712
SAEs0001
MAAEs65910
AESIs1100
AEs Leading to Study Discontinuation0010
AEs Leading to Discontinuation of Study Injection1010

Adverse events

Collected over Day 1 up to Day 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mRNA-1273.712 - Placebo Sequence: mRNA-1273.7120/500 (0%)0/500 (0%)0/500 (0%)
mRNA-1273.712 - Placebo Sequence: Placebo0/460 (0%)0/460 (0%)0/460 (0%)
Placebo - mRNA-1273.712 Sequence: Placebo0/497 (0%)0/497 (0%)0/497 (0%)
Placebo - mRNA-1273.712: mRNA-1273.7120/454 (0%)1/454 (0.2%)0/454 (0%)
Most frequent serious events
Most frequent serious events
EventmRNA-1273.712 - Placebo Sequence: mRNA-1273.712mRNA-1273.712 - Placebo Sequence: PlaceboPlacebo - mRNA-1273.712 Sequence: PlaceboPlacebo - mRNA-1273.712: mRNA-1273.712
Suicidal IdeationPsychiatric disorders0/5000/4600/4971/454

Baseline characteristics

Randomization Set: Included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)Sequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712Total
Mean19.7 ± 5.7320.0 ± 5.7119.8 ± 5.72
Age, Customized
Age, Customized(Participants)Sequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712Total
In utero000
Preterm newborn infants (gestational age < 37 wks)000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)235215450
Adults (18-64 years)265285550
From 65-84 years000
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712Total
Female266272538
Male234228462
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712Total
Hispanic or Latino6879147
Not Hispanic or Latino423417840
Unknown or Not Reported9413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence 1: mRNA-1273.712 Then PlaceboSequence 2: Placebo Then mRNA-1273.712Total
White320334654
Black or African American132108240
Asian191433
American Indian or Alaska Native134
Native Hawaiian or Other Pacific Islander112
Multiple213051
Other3710
Not Reported336
08

Study locations

24 sites
  • Velocity Clinical Research, Phoenix
    Phoenix, Arizona 85006, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research, San Diego
    La Mesa, California 91942, United States
  • Velocity Clinical Research, Banning
    San Bernardino, California 82408, United States
  • Velocity Clinical Research, Washington DC
    Washington D.C., District of Columbia 20016, United States
  • Velocity Clinical Research, Savannah
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research, Boise
    Meridian, Idaho 83642, United States
  • Velocity Clinical Research, Valparaiso
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research, Covington
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research, Lafayette
    Lafayette, Louisiana 70508, United States
  • Velocity Clinical Research, New Orleans
    New Orleans, Louisiana 70119, United States
  • Velocity Clinical Research, Gulfport
    Gulfport, Mississippi 39503, United States
  • Velocity Clinical Research, Grand Island
    Grand Island, Nebraska 68803, United States
  • Velocity Clinical Research, Lincoln
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research, Albuquerque
    Albuquerque, New Mexico 87107, United States
  • Velocity Clinical Research, Syracuse
    East Syracuse, New York 13057, United States
  • Velocity Clinical Research, Durham
    Durham, North Carolina 27701, United States
  • Velocity Clinical Research, Cleveland
    Beachwood, Ohio 44122, United States
  • Velocity Clinical Research, Cincinnati, Blue Ash
    Blue Ash, Ohio 45242, United States
  • Velocity Clinical Research, Cincinnati
    Cincinnati, Ohio 45246, United States
  • Velocity Clinical Research, Anderson
    Anderson, South Carolina 29621, United States
  • Velocity Clinical Research, Abilene
    Abilene, Texas 79606, United States
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah 84088, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jan 2025, 3 months.

Results were first posted in Feb 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 10, 2024
StartActual
Oct 8, 2024
Primary completionActual
Jan 20, 2025
CompletionActual
Jan 20, 2025
Results first posted
Feb 4, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06634797
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Oct 8, 2024
Primary completion
Jan 20, 2025
Completion
Jan 20, 2025
Results posted
Feb 4, 2026
Last update
Feb 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion